{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"

Kontinuierliches vs. intermittierendes\n Neuromonitoring zur Reduktion der passageren Recurrenspareserate in der Schilddrüsenchirurgie – eine prospektive, randomisierte, kontrollierte, multizentrische klinische Studie (CITY-Studie)

DRKS00033520

\n \n \n
","eudractNumber":null,"id":9864,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-15T09:08:10+02:00","shortTitle":"CITY Trial","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Langzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation","eudractNumber":null,"id":1659,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02863692","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-07-01T10:59:06+02:00","shortTitle":"CLL-Registry [DCLLSG Register]","therapeutical":false,"therapyLines":[]},{"active":true,"description":"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL): CLL-16 STUDIE DER DCLLSG","eudractNumber":"2020-004360-26","id":8660,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT05197192","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-25T14:28:21+02:00","shortTitle":"CLL16","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \nadjustment of treatment duration to improve outcomes","eudractNumber":"2023-510294-34","id":11270,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-11T11:42:59+02:00","shortTitle":"CLL18 / MOIRAI-TRIAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A prospective observational trial to assess treatment sequences and factors that impact
overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line
studies of the GCLLSG","eudractNumber":null,"id":12152,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06792994","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-06-22T15:08:27+02:00","shortTitle":"CLL2000","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien","eudractNumber":null,"id":3460,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-01-01T11:09:29+01:00","shortTitle":"CML VI - Registerstudie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

NCT-COMPASS:\ndeCOMPressing stomA und zweistufige elektive Resektion vs. Notfall-Resektion\nbei Patienten mit linksseitigem obstruktivem Dickdarmkrebs

DRKS00031827


","eudractNumber":null,"id":9179,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-01-31T10:54:20+01:00","shortTitle":"COMPASS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.","eudractNumber":null,"id":10267,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT06181734","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-09-13T09:23:35+02:00","shortTitle":"CONFIDHENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"COSS Register [COSSIRP]
= Klinisches Register für Kinder, Jugendliche \nund Erwachsene mit Osteosarkomen und Knochentumoren. Das COSS-Register \nbeinhaltet keine Vorgaben an Diagnostik oder Therapie. [s. Homepage der Cooperative OsteoSarkom Studiengruppe, COSS]
","eudractNumber":null,"id":948,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2005-10-01T13:19:16+02:00","shortTitle":"COSS Register - COSSIRP","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Veränderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]}]},"initialUrl":"/api/studies?ifs=lym4&lang=de&page=7&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

Kontinuierliches vs. intermittierendes\\n Neuromonitoring zur Reduktion der passageren Recurrenspareserate in der Schilddrüsenchirurgie – eine prospektive, randomisierte, kontrollierte, multizentrische klinische Studie (CITY-Studie)

DRKS00033520

\\n \\n \\n
\",\"name\":\"CITY Trial\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9864\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Langzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation\",\"name\":\"CLL-Registry [DCLLSG Register]\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/1659\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL): CLL-16 STUDIE DER DCLLSG\",\"name\":\"CLL16\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8660\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \\nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \\nadjustment of treatment duration to improve outcomes\",\"name\":\"CLL18 / MOIRAI-TRIAL\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11270\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A prospective observational trial to assess treatment sequences and factors that impact
overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line
studies of the GCLLSG\",\"name\":\"CLL2000\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/12152\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien\",\"name\":\"CML VI - Registerstudie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/3460\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

NCT-COMPASS:\\ndeCOMPressing stomA und zweistufige elektive Resektion vs. Notfall-Resektion\\nbei Patienten mit linksseitigem obstruktivem Dickdarmkrebs

DRKS00031827


\",\"name\":\"COMPASS\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9179\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.\",\"name\":\"CONFIDHENCE\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10267\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"COSS Register [COSSIRP]
= Klinisches Register für Kinder, Jugendliche \\nund Erwachsene mit Osteosarkomen und Knochentumoren. Das COSS-Register \\nbeinhaltet keine Vorgaben an Diagnostik oder Therapie. [s. Homepage der Cooperative OsteoSarkom Studiengruppe, COSS]
\",\"name\":\"COSS Register - COSSIRP\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/948\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Klinische Plattform zur Erforschung molekularer Veränderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs\",\"name\":\"CRISP\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/3383\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?ifs=lym4&page=8\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}